DBV Technologies announced the receipt of Written Responses from the FDA on key study design elements for the COMFORT or Characterization of the Optimal Management of Food Allergy Relief and Treatment, Toddlers and COMFORT Children supplemental safety studies in 1 – 3-year-olds and 4 – 7-year-olds, respectively, with a peanut allergy. The Company also reported financial results for the second quarter and the first half of 2023. The quarterly and half-year financial statements were approved by the Board of Directors on July 28. T
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DBVT:
- DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results
- DBVT Earnings this Week: How Will it Perform?
- DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update
- Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023
- Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
